passages.id: split_6_test_946_passage
passages.type: progene_text
passages.text: After 52 weeks of treatment , lamivudine recipients were more likely than placebo recipients to have a histologic response ( 52 percent vs. 23 percent , P < 0.001 ) , loss of hepatitis B e antigen ( HBeAg ) in serum ( 32 percent vs. 11 percent , P = 0.003 ) , sustained suppression of serum hepatitis B virus ( HBV ) DNA to undetectable levels ( 44 percent vs. 16 percent , P < 0.001 ) , and sustained normalization of serum alanine aminotransferase levels ( 41 percent vs. 7 percent , P < 0.001 ) , and they were less likely to have increased hepatic fibrosis ( 5 percent vs. 20 percent , P = 0.01 ) .